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Abstract: Psoriatic arthritis (PsA) is a chronic immune-mediated disease manifesting as joint
inflammation with functional impairment associated with psoriasis. Recently, PsA has emerged
as a systemic disease with several comorbidities, such as cardiovascular diseases and metabolic
disorders. Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD)
directed against phosphodiesterase 4 (PDE4) with demonstrated efficacy and safety in PsA and
psoriasis. We report the case of a patient with PsA manifesting as arthritis, dactylitis, mild psoriasis
and a significantly reduced health-related quality of life (HRQoL). Treatment with apremilast in
association with methotrexate led to a quick improvement of joint and skin involvement with a stable
amelioration of HRQoL. Furthermore, we observed a persistent favorable shift of serum lipid profile.
Our observations suggest that apremilast is effective in controlling mild skin and joint involvement,
including dactylitis, and suggest a potentially advantageous metabolic effect in patients with PsA.
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1. Introduction
Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory arthropathy associated with
psoriasis. It is characterized by multiple manifestations such as peripheral and/or axial arthritis,
enthesitis, dactylitis, psoriasis, and nail involvement. In recent decades it has become clear that PsA is
a systemic disease associated with several co-morbidities, such as cardiovascular (CV) diseases and
metabolic disorders, that overall negatively impact survival. Furthermore, PsA often affects patients’
health-related quality of life (HRQoL) [1,2].
Despite the advances in the treatment of PsA with conventional synthetic (cs) disease-modifying
anti-rheumatic drugs (DMARDs) and biological (b) DMARDs, inadequate response, drug intolerance
and therapeutic resistance have led to the development of new molecules such as apremilast, a
targeted synthetic (ts) DMARD [3]. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor approved
for the treatment of PsA as a second-line agent after failure of csDMARDs and a contraindication
to bDMARDs, particularly if the patient presents peripheral arthritis, enthesitis or dactylitis [4–6].
Apremilast has demonstrated effectiveness in the treatment of mild-moderate PsA, a favorable safety
profile and emerging advantageous metabolic effects in randomized controlled trials (RCTs) [7–9].
However, to date, there have been few real-life reports.
We here report the case of a patient with PsA with mild skin and joint involvement safely treated
with apremilast in association with methotrexate, leading to a quick clinical response, a considerable
amelioration of HRQoL and a favorable serum lipid profile. Our observations are relevant because
they support the efficacy of apremilast in the treatment of mild-moderate psoriasis and PsA and report
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for the first time a possible metabolic effect on serum lipid profile. This case report has been written
and edited following the case report (CARE) writing guidelines [10].
2. Case Report
We present the case of a 45-year-old Caucasian man suffering from psoriasis for more than 20 years
at the time of the first visit. No relevant comorbidities were found at history collection, apart from
benign prostatic hyperplasia, for which he is treated with tamsulosine. He was initially diagnosed and
followed-up by dermatologists, who treated him with topical corticosteroids and salicylic acid for skin
involvement and systemic corticosteroids for resistant lesions as needed (Figure 1).
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Figure 1. Case report timeline. Clinical course (left) and interventions (right) are described. Adverse
effects are framed and written in italics. The first referral, the last follow-up visit, and the 4 week
follow-up examination are reported in bold. Definitions: cyclosporine A (CySA); non-steroidal
anti-inflammatory drugs (NSAIDs); methotrexate (MTX); psoriasis area severity index (PASI); disease
activity in psoriatic arthritis (DAPSA); weeks (wk); months (mo).
The skin component had always been <30% of the total body surface area (BSA). The patient
reported distress in personal and social r lationships with consequently reduced HRQoL. After ten
years, he star ed experiencing dactylitis of feet and recurre t arthritis of th small joints of hands,
shoulders and knees, together with inflammatory morning stiffness lasting around one hour, with
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negative rheumatoid factor (RF); thus fulfilling ClASsification criteria for Psoriatic ARthritis CASPAR
criteria for PsA [11]. He was referred to the rheumatology outpatient clinic of another hospital
and treated with indomethacine and systemic corticosteroids as needed for about five years, and
then achieved complete remission of joint symptoms. Three years later, because of a flare of joint
involvement (episodes of peripheral arthritis and dactylitis of the small joints of hands and feet
once per week) and skin involvement, he was started on methotrexate 10 mg weekly with folate
supplementation, in combination with cyclosporine 200 mg daily, with reduced extension and severity
of skin lesions and decreased frequency of arthritis flares to once per month. However, he did not
reach complete remission. Shortly after initiation, due to a 2-fold increase of liver enzymes (hepatitis
excluded based on abdomen ultrasound and hepatitis B and C viral profile), methotrexate was reduced
to 7.5 mg weekly [12]. The reduced methotrexate regimen led to normalization of the liver enzymes
but was ineffective in controlling both skin and joint involvement. Two years later, due to elevated
arterial pressure values (up to 150/90 mmHg) and serum creatinine increase >30% of baseline value
(up to 1.4 g/L), cyclosporine was stopped.
The following year, he referred to our outpatient clinic for skin and joint flare. At referral, physical
examination demonstrated mild psoriasis of trunk, arms and legs, with a psoriasis area severity index
(PASI) score of 5.1 (Figure 2), dactylitis of the third digit of the left foot and arthritis of the third
interphalangeal joint of the left hand, which, together with a normal C reactive protein (CRP), activity
visual analogue scale (VAS) and pain VAS of 4 and 4.5 respectively, accounted for a disease activity in
psoriatic arthritis (DAPSA) score of 12 (low disease activity) [13].
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Figure 2. Psoriatic lesions of the trunk (left) and of the right elbow (right) at baseline and after 4 weeks,
6 months and 18 months of treatment with apremilast in combination with methotrexate. In the case of
the right upper limb, the lesion has completely healed.
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Laboratory tests showed no relevant alterations. Radiographic assessment of hands and feet
showed no erosions and no signs of axial involvement were found at magnetic resonance imaging
(MRI). Ultrasound imaging of the third metacarpophalangeal (MCP) joint showed inflammation of the
joint and of the peritendon of the extensor tendon (Figure 3a).
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Figure 3. Ultrasound dorsal scan of the third metacarpophalangeal joint of the right hand of our patient.
Swelling of the periarticular tissues, power doppler signal (red dots) of the joint and in the peritendon
of the extensor of the finger were more evident at baseline (a). After 6 months, the power doppler
signal and the periarticular swelling were considerably reduced (b).
Considering that the patient failed to respond to two DMARDs (cyclosporine and methotrexate),
that he refused a parenteral drug, that he presented mild skin and joint involvement, no bone erosions,
dactylitis and no axial involvement, apremilast was chosen [4–6]. At baseline, the EQ-5D questionnaire
reported altered HRQoL, with some difficulties in otility, no difficulties in self-care and some
difficulties in usual activities, moderate pain/discomfort and moderately anxious/depressed mood.
Patient’s global health (GH) VAS was 60 and pain VAS was 45 (Figure 4). Furthermore, the patient
was screened at baseline for CV risk; carotid arterial doppler ultrasound demonstrated only intimal
thickening of the left bulb and 24 h blood pressure monitoring demonstrated mild systolic and diastolic
daily hypertension for which he started lercanidipine 10 mg/daily. At baseline, total cholesterol (TC)
and triglyceride (TG) serum levels were 173 mg/dL and 113 mg/dL respectively, and TC/high density
lipoprotein (HDL) ratio was 4.94 (Table 1). After 4 weeks, the extension and severity of erythema
and infiltration of psoriatic plaques were substantially reduced (PASI 2.5, Figure 2). Furthermore, the
patient reported a marked improvement of joint involvement with no further episodes of arthritis or
dactylitis, although inflammatory morning stiffness persisted (DAPSA 6.0). At the 2-month follow-up,
the patient reported several side effects such as mild headache, dizziness and hypotension and, due to
further amelioration of the skin and joint involvement he stopped apremilast, which was restarted
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shortly after, due to worsening of psoriasis (PASI 3.0) and occurrence of a new joint flare (DAPSA 10).
At the time he was still taking methotrexate 7.5 mg weekly. At the 6-month follow-up he reported
no arthritis flares and no inflammatory morning stiffness. At physical examination, the third MCP
joint was swollen but not tender (DAPSA 3), and ultrasound imaging showed reduction of joint and
soft tissue inflammation (Figure 3b). A further improvement of skin involvement was observed and
reported by the patient (PASI 1.2, Figure 2). During the follow-up, we observed an amelioration of the
serum lipid profile already after 4 weeks, with a 5.8% reduction of TC and a reduction of TC/HDL
ratio, and after 12 months, a further reduction of TC, LDL and TG values of 15.6%, 25.7% and 17.7%
respectively, and a 20% increase of HDL levels compared to baseline values. TC/HDL ratio reached
the favorable value of 3.48, as shown in Table 1. We even observed a 5% weight loss—although our
patient already had a normal baseline weight and body mass index (BMI)—reaching a final normal
weight with a normal body mass index (BMI 21.5). After 12 months, the clinical manifestations were
stable. We therefore decided to stop methotrexate, but the patient experienced a slight relapse of both
skin and arthritis (PASI 2.5, DAPSA 6), shortly after. Therefore, although dosage was low (7.5 mg),
we reintroduced methotrexate, leading at the 18-month follow-up to stable minimal disease activity
with PASI 75 and joint remission (PASI 1.2, DAPSA 2) [11,13] and a dramatic improvement in HRQoL
(Figure 4).J. Clin  Med. 2019, 8, x FOR PEER REVIEW 6 of 10 
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Table 1. Serum lipid profile of the patient at baseline and during follow-up after the introduction of
apremilast. The percentage of reduction/increase of the serum levels are reported.
Baseline 4 Weeks 6 Months 12 Months
TC mg/dL (% reduction) 173 163 (5.8) 153 (11.6) 146 (15.6)
HDL mg/dL (% increase) 35 34 (−2.86) 45 (28.6) 42 (20)
LDL mg/dL (% reduction) 115 101 (12.2) 98 (14.8) 85.4 (25.7)
TG mg/dL (% reduction) 113 118 (−4.4) 50 (55.7) 93 (17.7)
TC/HDL ratio 4.94 4.79 3.40 3.48
TC total cholesterol, HDL high density lipoprotein, LDL low density lipoprotein, TG triglyceride.
3. Discussion
Apremilast was quickly effective in controlling mild skin and joint involvement, including
dactylitis, and led to HRQoL improvement, in line with previous literature [7–9,14]. Side effects in
our patient were mild and temporary and no laboratory pre-screening or ongoing monitoring were
necessary, due to the limited organ toxicity [7].
PsA is associated with a higher prevalence of metabolic syndrome, obesity, diabetes mellitus
and abnormal serum lipid levels, in particular hypertriglyceridemia, when compared to rheumatoid
arthritis (RA) patients [15–17]. Our patient showed a baseline unfavorable TC/HDL ratio, very close
to the proposed cut-off of >5 for high risk of CV events, although TC and TG serum levels were still
in the normal range [18,19]. It is common knowledge that PsA is associated with a high prevalence
of metabolic syndrome, obesity, diabetes mellitus and abnormal serum lipid levels, specifically
hypertriglyceridemia [17–19]. Metabolic syndrome and psoriasis share a chronic inflammatory state,
characterized by production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α)
and interleukin (IL)-6 [20]. In a study comparing RA and PsA patients from the Consortium of
Rheumatology Researchers of North America (CORRONA) registry, a higher proportion of patients
in the PsA than in the RA group was found to have significantly higher mean TG serum levels,
hypertriglyceridemia, and lower HDL serum levels with all these findings not correlated with the
BMI of patients [17]. The higher prevalence of metabolic syndrome in PsA compared to RA patients
could be explained by the presence of both skin and joint inflammation in patients with PsA, although
different pathogenic mechanisms in the two diseases are likely involved [15–17]. Since the first month
of treatment with apremilast, we observed a gradual and consistent TC, LDL, TG and TC/HDL ratio
reduction, along with an increase in HDL serum levels.
Apremilast is a tsDMARD directed against PDE4 that works by blocking the degradation of cyclic
adenosine 3′,5′-monophosphate (cAMP) to adenosine 3′,5′-monophosphate AMP, thus increasing
intracellular cAMP levels, which in turn activate protein kinase A (PKA) leading to the phosphorylation
of cAMP response element binding protein. This eventually leads to the inactivation of nuclear factor
κB (NF-κB) activity in plasmacytoid dendritic cells and T-cells, and the reduction of Th1-derived
synthesis of pro-inflammatory cytokines (Figure 5) [21]. PDE4 also acts as a critical regulator of
metabolic processes [22–25]. In the liver, the increase in cAMP levels promotes AMP kinase (AMPK)
activity, thus inhibiting the accumulation of lipids via the regulation of lipid metabolism-related
factors, such as sterol regulatory element-binding protein 1 (SREBP1) [26]. Non-alcoholic fatty liver
disease (NAFLD) is strongly associated with metabolic syndrome [27] and both NAFLD and metabolic
syndrome have a high prevalence in psoriasis and in particular in those patients who also have
PsA [28,29]. Intriguingly, PDE4 inhibition has been demonstrated to have an anti-inflammatory effect
also in non-alcoholic steatohepatitis (NASH) [30].
In fat tissue, the raise in cAMP levels induced by cAMP-PKA phosphorylation activates
hormone-sensitive lipase (HSL), thus increasing lipolysis, the process responsible for the hydrolysis of
the stored TG to free fatty acids (FFA) and glycerol (Figure 5) [25,31]. Our patient, who already had
a normal BMI, also experienced a slight loss of weight only partly due to mild gastrointestinal side
effects, which resolved after 6 months of treatment. However, he did not report any diet modification.
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Figure 5. Overview of apremilast mechanism of action in psoriatic arthritis in different systems.
Definitions: adenosine monophosphate kinase (AMPK); cyclic adenosine monophosphate (cAMP);
cAMP response element-binding (protein) (CREB); free fatty acids (FFA); hormone-sensitive lipase
(HSL); nuclear factor κB (NF-κB); phosphodiesterase 4 (PDE4); phosphokinase A (PKA); sterol
regulatory element-binding protein 1 (SREBP1); tumor necrosis factor-alpha (TNF-α).
Cholesterol efflux capacity (CEC) is the ability of HDL to remove cholesterol out of macrophage
foam cells and is impaired in atherosclerosis [32]. A very recent study demonstrated a reduced
CEC in patients with NAFLD, thus providing a proof of concept of the link between NAFLD and
the development of atherosclerosis. Notably, there is evidence that PDE4 inhibition may lead to
increases in ATP cassette binding protein 1 (ABCA1) expression and cholesterol efflux mediated by
apolipoprotein A-I, which is responsible for the removal of excess cholesterol from macrophage foam
cells in the arterial wall [33].
These mechanisms may have led in our patient to the reduction of TG serum levels and the
normalization of TC/HDL ratio. Although our data need to be confirmed with further follow-up and
observation l studies, these effects may contribute to a reduction of the development and progression
of dyslipidemia, obesity and steatohepatitis in patients with PsA, possibly reducing CV risk in these
patients [1,25].
In our case, apremilast was more effective when co-administered with methotrexate than alone.
This observation could be explained by the fact that although both drugs increase intracellular cAMP,
they exert different mechanisms of action: apremilast inhibits PDE4-mediated cAMP degradation;
methotrexate increases adenosine levels, in particular via the activation of the adenosine 2A
receptor [34]. The safety of this combination has already been demonstrated by pharmacokinetic
studies [35].
Finally, HRQoL improved considerably and constantly during the 18-month follow-up (Figure 4).
This is an important issue because the patient reported the reduction in HRQoL to be one of the main
complaints at referral and it is consistently one of the main characteristics of PsA [1].
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4. Conclusions
To the best of our knowledge, this is the first report of a possible metabolic effect of apremilast on
serum lipid profile in a patient with PsA treated for mild skin and joint involvement. Future studies
may be useful to better define the use of apremilast in patients with PsA and metabolic alterations.
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